Literature DB >> 34003714

Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series.

Anthony S Zembillas1, Stefanie M Thomas2, Seth J Rotz2, Ilia N Buhtoiarov2, Rabi Hanna2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34003714      PMCID： PMC8711132          DOI： 10.1080/08880018.2021.1927271

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN： 0888-0018            Impact factor:   1.969


× No keyword cloud information.
  7 in total

1.  Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

Authors:  Véronique Minard-Colin; Anne Aupérin; Marta Pillon; G A Amos Burke; Donald A Barkauskas; Keith Wheatley; Rafael F Delgado; Sarah Alexander; Anne Uyttebroeck; Catherine M Bollard; József Zsiros; Monika Csoka; Bernarda Kazanowska; Alan K Chiang; Rodney R Miles; Andrew Wotherspoon; Peter C Adamson; Gilles Vassal; Catherine Patte; Thomas G Gross
Journal:  N Engl J Med       Date:  2020-06-04       Impact factor: 91.245

Review 2.  Management of oral mucositis in pediatric patients receiving cancer therapy: A systematic review and meta-analysis.

Authors:  Fatemeh Mazhari; Alireza Sarraf Shirazi; Mahboubeh Shabzendehdar
Journal:  Pediatr Blood Cancer       Date:  2018-11-12       Impact factor: 3.167

3.  Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.

Authors:  Saroj Vadhan-Raj; Jonathan Trent; Shreyaskumar Patel; Xiao Zhou; Marcella M Johnson; Dejka Araujo; Joseph A Ludwig; Shana O'Roark; Ann M Gillenwater; Carlos Bueso-Ramos; Adel K El-Naggar; Robert S Benjamin
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

4.  Palifermin for oral mucositis after intensive therapy for hematologic cancers.

Authors:  Ricardo Spielberger; Patrick Stiff; William Bensinger; Teresa Gentile; Daniel Weisdorf; Tarun Kewalramani; Thomas Shea; Saul Yanovich; Keith Hansen; Stephen Noga; John McCarty; C Frederick LeMaistre; Eric C Sung; Bruce R Blazar; Dieter Elhardt; Mon-Gy Chen; Christos Emmanouilides
Journal:  N Engl J Med       Date:  2004-12-16       Impact factor: 91.245

5.  Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients.

Authors:  Dazhi Liu; Brian Seyboth; Sherry Mathew; Stephen W Gilheeney; Alexander J Chou; Esther Drill; Rachel Kobos
Journal:  J Pediatr Hematol Oncol       Date:  2017-05       Impact factor: 1.289

6.  Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.

Authors:  Parnian Zia-Amirhosseini; David D Hurd; Margaret Salfi; Tsui Chern Cheah; Jeffrey Aycock; Alessandra Cesano
Journal:  Pharmacotherapy       Date:  2007-10       Impact factor: 4.705

7.  The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children.

Authors:  Wael Saber; Mei-Jie Zhang; Patricia Steinert; Min Chen; Mary M Horowitz
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-07       Impact factor: 5.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.